Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial

CONCLUSION: Addition of pazopanib to etoposide and cyclophosphamide could be a novel oral combination for metronomic therapy for platinum resistant/refractory EOC.TRIAL REGISTRATION: CTRI/2017/10/010219.PMID:34088513 | DOI:10.1016/j.ygyno.2021.05.025

Source: Gynecologic Oncology - June 5, 2021 Category: Cancer & Oncology Authors: Aparna Sharma Mayank Singh Ravi Chauhan Prabhat Singh Malik Sachin Khurana Sandeep Mathur Sunesh Kumar Vishnubhatla Sreenivas Lalit Kumar Source Type: research